Monitoring of DC and T cell functions in healthy controls and patients with prostate cancer treated with GM-CSF transduced allogeneic vaccines and anti-CTLA-4
Withdrawn
- Conditions
- onderzoek van immuuncellen van gezonde mensennot applicable
- Registration Number
- NL-OMON34152
- Lead Sponsor
- Vrije Universiteit Medisch Centrum
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Withdrawn
- Sex
- Not specified
- Target Recruitment
- 12
Inclusion Criteria
Healthy men without a history of cancer or auto-immune diseases
age 65-75 years
Exclusion Criteria
Cancer patients
Patients with auto-immune diseases
women
Study & Design
- Study Type
- Observational invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>FACS analysis the following markers will be measured on dendritic cells and T<br /><br>cells:<br /><br>a) peripheral blood dendritic cells and monocytes:<br /><br>1) CD1c high/CD14neg/BDCA1+ cells (cDC1)<br /><br>2) CD1c high/CD14neg/BDCA3+ cells (cDC2)<br /><br>3) CD1c high/CD14low/MDC-8+ cells (cDC3)<br /><br>4) CD1c neg/CD14neg/BDCA2+ cells (plasmacytoid cells (pDC)) en<br /><br>5) CD11c+/CD14+ monocytes.<br /><br>b) peripheral blood CD4+ en CD8+ T cells (CD3, CD4, CD8, CD45RA, CD45RO, CD27,<br /><br>CD25, and HLA-DR, CTLA-4, PD-1) en regulatory T cells (CD4+/CD25high/FoxP3+)</p><br>
- Secondary Outcome Measures
Name Time Method <p>NA</p><br>